Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2017

Nov 17, 2017

34238_dirs_2017-11-17_240e34f2-dbc1-41fa-87cd-8886ed0d513c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2017-11-15

Reporting Person: Levine Mitchell S (Chief Financial Officer)